Oral quinine sulfate for the treatment of electrical storm and prevention of recurrent shocks in Brugada syndrome after failed cilostazol therapy

Shenthar, Jayaprakash; Chakali, Siva Sankara; Acharya, Debashish; Parvez, Javed; Banavalikar, Bharatraj

doi:10.1016/j.hrcr.2017.07.005

Cited by 12 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…60 In humans, quinine is effective in suppressing both spontaneous and inducible ventricular arrhythmias without the proarrhythmic potential of QT prolongation, torsade de pointes, or heart block. 61 In one case report, 32 monotherapy with quinine sulphate was effective in preventing electrical storm and recurrent ICD shocks. This medication also resulted in normalisation of ST-segment elevation.…”

Section: Quinine Sulphatementioning

confidence: 99%

“…This medication also resulted in normalisation of ST-segment elevation. 32 The use of intravenous quinine was reported for the acute management of an arrhythmic storm in a 10-year-old child. 62…”

Section: Quinine Sulphatementioning

confidence: 99%

“…52,[72][73][74][75][76][77] However, the failure of cilostazol 200 mg daily in preventing a VF storm has also been reported. 32,80 Worthy of mention, cilostazol can cause symptomatic palpitations, 77 and its long-term effects have not been reported. The combined use of cilostazol and bepridil has been reported to attenuate cilostazol induced palpitations (see below).…”

Section: Beta Adrenergic Agonistsmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacological Therapy in Brugada Syndrome

Brodie

Michowitz

Belhassen

2018

Arrhythmia &Amp; Electrophysiology Review

View full text Add to dashboard Cite

Brugada syndrome (BrS) is a cardiac disease caused by an inherited ion channelopathy associated with a propensity to develop ventricular fibrillation. Implantable cardioverter defibrillator implantation is recommended in BrS, based on the clinical presentation in the presence of diagnostic ECG criteria. Implantable cardioverter defibrillator implantation is not always indicated or sufficient in BrS, and is associated with a high device complication rate. Pharmacological therapy aimed at rebalancing the membrane action potential can prevent arrhythmogenesis in BrS. Quinidine, a class 1A antiarrhythmic drug with significant Ito blocking properties, is the most extensively used drug for the prevention of arrhythmias in BrS. The present review provides contemporary data gathered on all drugs effective in the therapy of BrS, and on ineffective or contraindicated antiarrhythmic drugs.

show abstract

Section: Quinine Sulphatementioning

confidence: 99%

Section: Quinine Sulphatementioning

confidence: 99%

Section: Beta Adrenergic Agonistsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological Therapy in Brugada Syndrome

Brodie

Michowitz

Belhassen

2018

Arrhythmia &Amp; Electrophysiology Review

View full text Add to dashboard Cite

show abstract

“…Quinidine, an AAD with blocking activity in the Ito and IKr currents, has been shown to prevent phase II re‐entry and ventricular fibrillation (VF) in in vitro studies of BrS 60 . Quinidine has rendered patients noninducible in 76% to 88% of patients with inducible VF at baseline EPS 61 . It has also successfully been used in certain clinical settings such as arrhythmic storms or multiple ICD discharges, or as an alternative to an ICD in children 62 .…”

Section: Long‐term Management and Prognosismentioning

confidence: 99%

“…60 Quinidine has rendered patients noninducible in 76% to 88% of patients with inducible VF at baseline EPS. 61 It has also successfully been used in certain clinical settings such as arrhythmic storms or multiple ICD discharges, or as an alternative to an ICD in children. 62 Ablation has been suggested as a possible therapeutic option.…”

mentioning

confidence: 99%

Atrial fibrillation in Brugada syndrome: Current perspectives

Vlachos

Mascia

Martin

et al. 2020

Cardiovasc electrophysiol

View full text Add to dashboard Cite

The incidence of atrial fibrillation (AF) in Brugada syndrome (BrS) has been reported at between 9% and 53% by different series, but the true prevalence is unknown. However, AF may be the presenting feature in some patients. The underlying mechanisms for AF may be a combination of multiple factors, genetic or acquired, that may impact upon autonomic function, atrial structure, and conduction velocities or other unknown factors. The presence of AF has been associated with a more malignant course, with a greater incidence of syncope and ventricular arrhythmias, thus acting as marker of more advanced disease. Regarding the management of patients with AF, antiarrhythmic drugs effective in preventing malignant arrhythmias in BrS such as quinidine or invasive treatment with pulmonary vein isolation (PVI) may be useful in AF treatment. In this review, we aim to present the current perspectives regarding the genetics, pathophysiology, management, and prognosis of AF in patients with BrS.

show abstract

Role of Catheter Ablation for Ventricular Arrhythmias in Brugada Syndrome

Chokesuwattanaskul

Nademanee

2021

Curr Cardiol Rep

View full text Add to dashboard Cite

Purpose of Review To discuss the role of catheter ablation in treating life-threatening ventricular arrhythmias associated with Brugada syndrome (BrS), by presenting recent findings of BrS arrhythmogenic substrate, mechanisms underlying ventricular arrhythmias, and how they can be treated with catheter ablation. Recent Findings Almost three decades ago when the clinical entity of Brugada syndrome (BrS) was described in patients who had abnormal coved-type ST elevation in the right precordial EKG leads in patients who had no apparent structural heart disease but died suddenly from ventricular fibrillation. Since its description, the syndrome has galvanized explosive research in this field over the past decades, driving major progress toward better understanding of BrS, gaining knowledge of the genetic pathophysiology and risk stratification of BrS, and creating significant advances in therapeutic modalities. One of such advances is the ability for electrophysiologists to map and identify the arrhythmogenic substrate sites of BrS, which serve as good target sites for catheter ablation. Subsequently, several studies have shown that catheter ablation of these substrates normalizes the Brugada ECG pattern and is very effective in eliminating these substrates and preventing recurrent VF episodes. Summary Catheter ablation has become an important addition for treatment of symptomatic BrS patients with recurrent VT/VF episodes.

show abstract

Oral quinine sulfate for the treatment of electrical storm and prevention of recurrent shocks in Brugada syndrome after failed cilostazol therapy

Cited by 12 publications

References 14 publications

Pharmacological Therapy in Brugada Syndrome

Pharmacological Therapy in Brugada Syndrome

Atrial fibrillation in Brugada syndrome: Current perspectives

Role of Catheter Ablation for Ventricular Arrhythmias in Brugada Syndrome

Contact Info

Product

Resources

About